Risk factors

Monopar Therapeutics (MNPR) risk factors

Item 1A of every Monopar Therapeutics 10-K on file, and what changed from one year to the next.

Open MNPR in Gloomberb →
  • FY2025 10-K risk factors

    82 risks, 2 dropped, 12 reworded since the prior year. Monopar's updated risk disclosures reflect higher accumulated losses, expanded share counts, and updated patent and tariff details for the ALXN1840 program.

    Filed Mar 27, 2026
  • FY2024 10-K risk factors

    84 risks. Monopar relies heavily on its ability to finance and develop its lead assets, particularly ALXN1840 and MNPR-101. The company faces high regulatory hurdles, reliance on third-party suppliers, and uncertainties in clinical trials and future commercialization.

    Filed Mar 31, 2025